Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noonan syndrome, the Ras-MAPK signalling pathway and short stature.

Hormone research - 1 Apr 2009

Binder Gerhard

Abstract excerpt

Short stature, with a mean final height almost two standard deviations below the normal mean, is a major feature of Noonan syndrome. The biological basis of the growth failure is not yet clear. The recent detection of mutations in the protein tyrosine phosphatase, non-receptor type 11 gene (PTPN1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carrier Proteins
Share to Down-Regulation
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasms

Share to Noonan Syndrome

Share to Oncogene Protein p21(ras)

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Identifiers

PMID: 19407499
DOI: 10.1159/000192439

Genes

PTPN11
SOS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19407499-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noonan syndrome, the Ras-MAPK signalling pathway and short stature.PMID 19407499Read ↗

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.Semantic proximity Read ↗

[Noonan syndrome: from phenotype to growth hormone therapy].Semantic proximity Read ↗

Noonan syndrome: relationships between genotype, growth, and growth factors.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.Semantic proximity Read ↗

Expanding the genetic spectrum of Noonan syndrome.Semantic proximity Read ↗

Abnormal growth in noonan syndrome: the challenge of optimal therapy.Semantic proximity Read ↗

PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

MECHANISMS IN ENDOCRINOLOGY: Novel genetic causes of short statureSemantic proximity Read ↗

Noonan syndrome: an update on growth and development.Semantic proximity Read ↗

PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.Semantic proximity Read ↗

Efficacy and safety of growth hormone therapy in children with Noonan syndrome.Semantic proximity Read ↗

[RAS/MAPK signal transduction pathway and its role in the pathogenesis of Noonan syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.